Here we describe small molecules with the ability to restore PGRN levels in PGRN haploinsufficient models in vitro and in vivo and the ability to correct aberrant lysosomal proteomes in FTD patient-derived cells. This evidence concerns the gene GRN and frontotemporal dementia.